Cargando…
Vasopressin surrogate marker copeptin as a potential novel endocrine biomarker for antidepressant treatment response in major depression: A pilot study
INTRODUCTION: Major depressive disorder (MDD) constitutes the leading cause of disability worldwide. Although efficacious antidepressant pharmacotherapies exist for MDD, only about 40-60% of the patients respond to initial treatment. However, there is still a lack of robustly established and applica...
Autores principales: | Agorastos, A., Sommer, A., Wiedemann, K., Demiralay, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470906/ http://dx.doi.org/10.1192/j.eurpsy.2021.1213 |
Ejemplares similares
-
Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study
por: Agorastos, Agorastos, et al.
Publicado: (2020) -
Arginine-vasopressin marker copeptin is a sensitive plasma surrogate of hypoxic exposure
por: Ostergaard, Louise, et al.
Publicado: (2014) -
Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome
por: Karbek, Basak, et al.
Publicado: (2014) -
Inverse autonomic stress reactivity in depressed patients with and without prior history of depression
por: Agorastos, A., et al.
Publicado: (2021) -
Arginine Vasopressin and Copeptin in Perinatology
por: Evers, Katrina Suzanne, et al.
Publicado: (2016)